Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.37 |
| ▸ | HPGD | P15428 | 8/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933804 | 0.80 | SSTR3 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL15848316 | 0.80 | SSTR3 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL15848318 | 0.80 | SSTR3 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL932655 | 0.75 | ABL1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL1908293 | 0.74 | LIPG (0.35) | — | |
| SCHEMBL1908290 | 0.74 | LIPG (0.35) | — | |
| SCHEMBL933284 | 0.74 | HPGDS (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL1980791 | 0.73 | HCRTR1 (0.35) | HCRTR1HCRTR2LMNARXFP1 | |
| SCHEMBL18813763 | 0.73 | LIPG (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL18813762 | 0.73 | LIPG (0.35) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | HCRTR1 4187/4885HCRTR2 4696/4885HPGD 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.